Unmet Needs and the Evolving Landscape in Acute Treatment of Migraine: Primary Care Professionals on the Front Line
Recorded April 17, 2021
Despite the disability and socioeconomic burden associated with migraine, underdiagnosis and undertreatment remain significant problems in clinical practice, and effective treatment can be elusive. Triptans—the longtime cornerstone of acute treatment—are ineffective, poorly tolerated, or contradicted in many patients, leading to low rates of use and high rates of discontinuation, with recent data suggesting that less than one-fourth of patients currently use prescription medication for acute migraine relief. Poor or inadequate acute migraine treatment can result in progression from episodic to chronic migraine or medication overuse headache.
While new approaches to migraine prophylaxis have understandably generated great excitement, equally important developments in acute migraine treatment have also emerged recently. Growing understanding of migraine pathophysiology has spurred the development of novel targeted therapies, including 5-HT1F receptor agonists and calcitonin gene-related peptide receptor agonists, drug classes that are free of the cardiovascular contraindications of older migraine medications. Triptans, too, have evolved, with delivery modifications that can improve bioavailability, speed of onset, and tolerability.
Family physicians and other primary care providers on the frontline of migraine care need to learn about the role that new and emerging treatments can play in optimizing clinical care for patients with migraine.
After participating in this activity, learners should be better able to:
- Appreciate the prevalence of migraine in a primary care setting
- Utilize established criteria to make differential diagnoses for migraine headache and to distinguish episodic from chronic migraine
- Assess the evidence regarding the potential benefits and risks of emerging acute migraine treatments
Susan Hutchinson, MD
Orange County Migraine & Headache Center
Stewart J. Tepper, MD, FAHS
Professor of Neurology
Geisel School of Medicine at Dartmouth
Susan Hutchinson, MD, serves as a consultant/advisory board member for Alder BioPharmaceuticals, Inc., Allergan, Inc., Amgen Inc., Biohaven Pharmaceuticals Inc., electroCore Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Promius Pharma, LLC, Supernus Pharmaceuticals, Inc., Theranica Bio-Electronics Ltd., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories, LLC.
She is also on the speakers’ bureaus for Allergan, Inc., Amgen Inc., electroCore Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Supernus Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.
Stewart J. Tepper, MD, FAHS, receives research grants from Allergan, Inc., Amgen, Inc., electroCore Inc., Eli Lilly and Company, Lundbeck Pharmaceuticals, Inc., Neurolief Ltd., Novartis Pharmaceuticals Corporation, Satsuma Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation.
Thank you for attending 2021 FamMed Forum!
Thank you for participating in the 2021 FamMed Forum. In order to complete this course and qualify for CME Credit, you must be logged into the website.
If the banner above shows "log in to enroll," please do so using the BLUE login button displayed on this page. All registered attendees for the live FamMed Forum are also enrolled in each FamMed Forum stand alone CME Course.
Begin by completing the Pre-test. Then watch the entire video lesson. Then complete the Post-test and proceed to Session Evaluation. Make sure you click "Submit" at the end of the evaluation before continuing to the claim for CME Credit.
Then complete the brief post-test. If you experience difficulty, please view the Site Navigation menu item.
Each recorded session will issue a separate CME Certificate. We are only offering AMA PRA Category 1 Credit(s)tm for the recorded stand-alone sessions.
If you have any difficulty or questions, please contact us by email by clicking here.